Concord Drugs Limited (BOM:538965)
India · Delayed Price · Currency is INR 78.33
+2.50 (3.30%)
At close: Sep 25, 2026
Concord Drugs Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Operating Revenue | 860.69 | 787.37 | 452.45 | 449.25 | 520.81 | 589.57 |
Other Revenue | 0 | 0 | 0 | - | - | 0.86 |
| 860.69 | 787.37 | 452.45 | 449.25 | 520.81 | 590.43 | |
Revenue Growth | 82.51% | 74.02% | 0.71% | -13.74% | -11.79% | 14.77% |
Cost of Revenue | 731.41 | 679.29 | 354.27 | 335.03 | 415.96 | 425.7 |
Gross Profit | 129.28 | 108.08 | 98.18 | 114.22 | 104.85 | 164.73 |
Selling, General & Admin | 53.4 | 49.71 | 46.35 | 60.76 | 49.19 | 48.91 |
Other Operating Expenses | 18.03 | 13.19 | 10.49 | 13.03 | 9.94 | 7.55 |
Operating Expenses | 84.92 | 76.56 | 71.14 | 89.35 | 75.38 | 125.59 |
Operating Income | 44.37 | 31.53 | 27.04 | 24.87 | 29.46 | 39.14 |
Interest Expense | -16.2 | -16.22 | -19.19 | -18.17 | -16.34 | -15.79 |
Interest & Investment Income | - | 0.33 | 0.14 | 0.09 | 0.06 | 0.12 |
Other Non Operating Income (Expenses) | 0.43 | -0.91 | -1.08 | -0.5 | -0.7 | -0.99 |
EBT Excluding Unusual Items | 28.6 | 14.73 | 6.91 | 6.29 | 12.49 | 22.48 |
Pretax Income | 28.6 | 14.73 | 6.91 | 6.29 | 12.49 | 22.48 |
Income Tax Expense | 8.08 | 4.18 | 3.55 | 1.57 | 2.63 | 6.54 |
Net Income | 20.51 | 10.55 | 3.36 | 4.72 | 9.86 | 15.94 |
Net Income to Common | 20.51 | 10.55 | 3.36 | 4.72 | 9.86 | 15.94 |
Net Income Growth | 380.85% | 213.80% | -28.82% | -52.08% | -38.19% | -51.42% |
Shares Outstanding (Basic) | 12 | 11 | 10 | 10 | 9 | 9 |
Shares Outstanding (Diluted) | 12 | 11 | 10 | 10 | 9 | 9 |
Shares Change | 18.52% | 11.48% | - | 7.35% | 6.53% | - |
EPS (Basic) | 1.72 | 0.95 | 0.34 | 0.47 | 1.06 | 1.82 |
EPS (Diluted) | 1.72 | 0.95 | 0.34 | 0.47 | 1.06 | 1.82 |
EPS Growth | 305.70% | 181.49% | -28.47% | -55.57% | -41.87% | -51.47% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Free Cash Flow | - | -69.16 | 13.89 | -2.26 | 8.06 | -16.82 |
Free Cash Flow Per Share | - | -6.20 | 1.39 | -0.23 | 0.87 | -1.92 |
Gross Margin | 15.02% | 13.73% | 21.70% | 25.42% | 20.13% | 27.90% |
Operating Margin | 5.16% | 4.00% | 5.98% | 5.54% | 5.66% | 6.63% |
Profit Margin | 2.38% | 1.34% | 0.74% | 1.05% | 1.89% | 2.70% |
Free Cash Flow Margin | - | -8.78% | 3.07% | -0.50% | 1.55% | -2.85% |
EBITDA | 57.87 | 45.19 | 41.34 | 40.43 | 45.72 | 56.79 |
EBITDA Margin | 6.72% | 5.74% | 9.14% | 9.00% | 8.78% | 9.62% |
D&A For EBITDA | 13.51 | 13.67 | 14.31 | 15.55 | 16.26 | 17.65 |
EBIT | 44.37 | 31.53 | 27.04 | 24.87 | 29.46 | 39.14 |
EBIT Margin | 5.16% | 4.00% | 5.98% | 5.54% | 5.66% | 6.63% |
Effective Tax Rate | 28.27% | 28.39% | 51.37% | 24.89% | 21.09% | 29.08% |
Revenue as Reported | 861.12 | 787.71 | 452.59 | 449.34 | 520.89 | 590.57 |